Key result
The PercuSurge distal protection device improved post-PCI TIMI-3 flow and reduced 30-day major adverse cardiac events compared to conventional PCI in patients with acute myocardial infarction.
Why the study?
Does a distal protection device improve angiographic outcomes and reduce adverse events in patients with AMI undergoing emergent PCI from 24 to 72 hours?
Cohort (n=174)
Single-blind
No
Does a distal protection device improve angiographic outcomes and reduce adverse events in patients with AMI undergoing emergent PCI from 24 to 72 hours?
The use of a distal protection device during emergent PCI for AMI between 24 and 72 hours improves angiographic outcomes and reduces 30-day major adverse cardiac events.
Answers are grounded in this paper and cite their sources.
May support distal protection in 24-72h AMI PCI; leaves open randomized confirmation before practice change.
Acute myocardial infarction (AMI) intervention is associated with a significant incidence of slow flow or no-reflow phenomenon. PercuSurge distal protection device (DPD) has recently been approved as an effective adjunct to AMI intervention within 24 h or in the clinical settings of saphenous vein graft intervention. In this study, we evaluate the efficiency and safety of PercuSurge DPD in coronary intervention in patients with AMI during emergent percutaneous coronary intervention (PCI) treatment from 24 to 72 h. This was a prospective cohort study of patients with AMI. 174 AMI patients who received emergent coronary intervention were divided into DPD and control group according to whether Percusurge DPD was attempted during emergency PCI. The basic clinical characteristics, angiographic results, and follow up data before discharge were compared. Thrombolysis in myocardial infarction (TIMI）grades and myocardial blush grades (MBG) were performed in all cases after emergency PCI. The device was successfully deployed in 78 of 87 patients, the visible red, white debris or red clastic thromboses were aspirated in 72 of 78 patients in DPD group. Post- PCI TIMI grades and MBG were significantly higher in DPD group than in control group. Post-PCI no-reflow, distal embolization and 30-day major adverse cardiac events were significantly higher in control group than in DPD group, whereas TIMI grades, MBG and minimal lumen diameter were significantly increased after using the export aspiration. PercuSurge DPD can be used effectively and safely in coronary intervention in the thrombus laden arteries such as patients with AMI during emergent PCI treatment from 24 to 72 h. Key words: Angioplasty, coronary artery, acute myocardial infarction, PercuSurge distal protection device, clinical trials.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2011) conducted a cohort in Acute myocardial infarction (n=174). PercuSurge distal protection device vs. Conventional percutaneous coronary intervention was evaluated on Post-PCI TIMI-3 flow (p=0.03). The PercuSurge distal protection device improved post-PCI TIMI-3 flow and reduced 30-day major adverse cardiac events compared to conventional PCI in patients with acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: